The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1263 articles
Ozempic, the semaglutide injection revolutionizing obesity treatment, delivers 15-20% weight loss but comes with gastrointestinal side effects and muscle loss risks. The SELECT trial shows a 20% drop in heart attacks and strokes for high-risk patients. Discover benefits, hidden risks, and long-term strategies for sustained success.
GLP-1 weight-loss drugs weren't meant to change restaurant menus, but they're doing just that in Denver and beyond. With appetites reset by Ozempic and similar meds, spots like Olive & Finch are prioritizing protein-packed small plates over supersized servings. Here's how the GLP-1 era is reshaping everyday eating.
Eli Lilly reports Mounjaro sales skyrocketing to $7.4 billion in Q4 2026, driven by explosive GLP-1 demand. New 2026 research links tirzepatide to liver inflammation resolution and reduced heart failure risks. Meanwhile, UK regulators ban unauthorized social media promotions of these prescription drugs.
Amazon Pharmacy is set to revolutionize prescription access by expanding same-day delivery to about 4,500 US cities and towns by the end of 2024, reaching nearly 2,000 new communities. This includes states like Idaho and Massachusetts, building on partnerships for GLP-1 obesity treatments with WeightWatchers. Patients managing metabolic health conditions can expect quicker delivery of essential medications.
In a $50 billion GLP-1 market dominated by injectables like Ozempic, Becca McCarthy is carving out space with Evolv—a natural pill for appetite control. Teaming with a molecular biologist, she's delivering GLP-1-like effects without stigma or synthetics. Here's how she's challenging the prescription-only model.
Meijer is making GLP-1 medications more affordable by accepting manufacturer savings programs for Ozempic and Wegovy, dropping costs to $199 per month for the first two months on lowest doses. The retailer also offers the newly approved oral Wegovy through the same program, starting at $149 out-of-pocket. This move aims to boost access to these popular weight loss injections amid rising demand.
Meat snacks have become the standout winner in America's GLP-1 consumption shift, surging to a $5.5 billion market as Ozempic and Wegovy users crave protein. Popcorn sales are plummeting amid this protein obsession. Discover the data, expert analysis, and how it's changing snacking habits.
Simon Cowell's latest video before the Britain's Got Talent 2025 finale has fans convinced he's developing 'Ozempic face' due to his noticeably slimmer features and changed eye shape. Social media erupts with comments from 2023 to 2025, even linking him to Ryan Seacrest's look. Despite the buzz, Cowell tells The Sun he's never tried Ozempic.
Novo Nordisk has filed a lawsuit against Hims & Hers Health Inc., accusing the telehealth company of breaching its U.S. patent on semaglutide used in blockbuster obesity drugs like Ozempic and Wegovy. Despite Hims scrapping plans for a copycat Wegovy pill, Novo claims the compounded versions remain dangerous and infringing. This legal battle highlights growing tensions over compounded GLP-1 drugs post-shortage.
